GlassScriptPhysician profile
Ghulam Ghous
NPI 1003260787
$1,617.08
in general payments reported to CMS, 2019-2025
27 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.57 · 2022: $13.84 · 2023: $487 · 2024: $595 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.69 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $235.34 | 2023-2024 | |
| Beigene USA, INC. | $173.60 | 2023 | Brukinsa |
| Adaptive Biotechnologies Corporation | $153.80 | 2023-2025 | Clonoseq |
| Jazz Pharmaceuticals INC. | $126.64 | 2024 | |
| Pfizer INC. | $121.47 | 2024-2025 | |
| Stemline Therapeutics INC. | $108.07 | 2024 | Elzonris |
| Genzyme Corporation | $103.66 | 2024 | |
| Gilead Sciences, INC. | $56.68 | 2019-2025 | Trodelvy |
| Beone Medicines USA, INC. | $55.44 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $53.46 | 2025 | |
| Abbvie INC. | $50.58 | 2025 | |
| Janssen Biotech, INC. | $42.86 | 2023-2025 | Rybrevant |
| Nuvation Bio INC. | $32.14 | 2025 | Ibtrozi |
| Kite Pharma, INC. | $27.13 | 2023 | |
| Glaxosmithkline, LLC. | $24.70 | 2025 | Ojjaara |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.07 | 2025 | |
| Caris Mpi, INC. | $22.52 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $21.56 | 2025 | Itovebi |
| Exelixis INC. | $19.98 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.96 | 2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $19.03 | 2025 | Monoferric |
| Immunocore Limited | $17.49 | 2025 | Kimmtrak |
| Puma Biotechnology, INC. | $17.13 | 2023 | |
| Array Biopharma INC | $15.70 | 2025 | Tukysa, Braftovi, Mektovi |
| Novartis Pharmaceuticals Corporation | $14.74 | 2024 | |
| Incyte Corporation | $13.84 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Ghous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.